• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMC
Click for more information
0.00% 7.5¢

IMMURON LIMITED - Announcements

Market Cap $21.88M  ! watchlist Created with Sketch. Add to my watchlist

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and... Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMC NASDAQ Listing on Hold Pending NASH Interim Analysis ResultsPRICE SENSITIVE01/06/17
IMC Trading HaltPRICE SENSITIVE30/05/17
IMC IMC Expands Agreement with US Army-3 Additional TherapeuticsPRICE SENSITIVE16/05/17
IMC Completion of Manufacturing of Drug Product for C-Diff TrialPRICE SENSITIVE10/05/17
IMC Immuron - New Investor Corporate Presentation (May 2017)09/05/17
IMC IMC Form F1 - US Registration Statement (Prelim. Prospectus)PRICE SENSITIVE09/05/17
IMC Immuron Files Amended Form F-1 and New Investor Presentation09/05/17
IMC Form 604 - Change in Substantial Shareholding (Authentics)05/05/17
IMC Form 603 - Initial Substantial Shareholder (Authentics)05/05/17
IMC Positive Results of IMM-124E in Acute Colitis StudiesPRICE SENSITIVE18/04/17
IMC Immuron Update on US Listing - Proceeding as Planned11/04/17
IMC Immuron Update on Listing - Process Proceeding as Planned11/04/17
IMC Immuron Files Amended Form F-1 with the SEC10/04/17
IMC Director Appointment - Prof. Ravi Savarirayan07/04/17
IMC Close of Recruitment of Phase II NASH TrialPRICE SENSITIVE06/04/17
IMC Appendix 4D - Half Year Report and Accounts - Dec 2016PRICE SENSITIVE28/02/17
IMC Immuron Completes Phase II NASH Clinical Trial RecruitmentPRICE SENSITIVE20/02/17
IMC Immuron Files Amended Form F-1 with the SEC09/02/17
IMC First Patient in Pediatric Fatty-Liver Phase II TrialPRICE SENSITIVE06/02/17
IMC NASH MOA Study commences with SanyalBio & Duke UniversityPRICE SENSITIVE19/01/17
IMC European/US Analyst - Immuron Moving to Forefront in NASH18/01/17
IMC Gilead Pays $100M NASH Related Milestone to Phenex09/01/17
IMC JNJ, BMS and Novartis Complete NASH Asset Transactions06/01/17
IMC Immuron Files Form F-1 with the SEC22/12/16
IMC Appendix 3B - Issue of Options Under ESOP09/12/16
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)07/12/16
IMC Appendix 3Y - Change of Director's Interest Notices (x4)02/12/16
IMC Appendix 3B - Issue of Rights Issue Options & ESOP Shares02/12/16
IMC Results of 2016 Annual General Meeting29/11/16
IMC 2016 AGM Presentation29/11/16
IMC Immuron Receives $1.6M R&D Tax Concession RefundPRICE SENSITIVE29/11/16
IMC Notice of 2016 Annual General Meeting-IMC.AX 28/10/16
IMC Immurons NASH Phase II Trial Achieves 100 Patient Milestone-IMC.AX PRICE SENSITIVE28/10/16
IMC Appendix 3Y - Change in Director's Interest Notice (DP)-IMC.AX 27/10/16
IMC Becoming a substantial holder-IMC.AX 17/10/16
IMC NASH Phase II Trial reaches 75% of Patient Recruitment-IMC.AX PRICE SENSITIVE10/10/16
IMC NASH Assets In Demand - Allergan Acquires Tobira for US$1.7B-IMC.AX 05/10/16
IMC IMC - ASX - Appendix 3B (Rights Issue)-IMC.AX 04/10/16
IMC Immurons $6M Rights Issue Closes Oversubscribed-IMC.AX PRICE SENSITIVE04/10/16
IMC Appendix 4E and Annual Report-IMC.AX PRICE SENSITIVE30/08/16
IMC Appendix 4G-IMC.AX 30/08/16
IMC Immuron Expands Collaborate with US Navy-IMC.AX PRICE SENSITIVE30/08/16
IMC US NIH to Fund Second IMC Fatty Liver Study - Pediatric NASH-IMC.AX PRICE SENSITIVE18/08/16
IMC Travelan to be Stocked by US Distributor Medique Products-IMC.AX PRICE SENSITIVE08/08/16
IMC Immuron to Seek Approval of Rights Issue Options at AGM-IMC.AX 02/08/16
IMC Immuron to Cooperate with Universities on Autism Research-IMC.AX PRICE SENSITIVE20/07/16
IMC Immuron to repay outstanding Convertible Note in cash-IMC.AX PRICE SENSITIVE18/07/16
IMC Form 604 -Change in Substantial Shareholding (Inverarey P/L)-IMC.AX 15/07/16
IMC Appendix 3Y - Change in Director's Interest Notices (x4)-IMC.AX 11/07/16
IMC Appendix 3B for Rights Issue & New Top 20 Shareholder List-IMC.AX 07/07/16
IMC Immuron Rights Issue Raises $5.33M-IMC.AX 05/07/16
IMC IMC Signs Shigella Vaccine Developmt Agreement with US Army-IMC.AX PRICE SENSITIVE21/06/16
IMC Immuron Newsletter - June 2016-IMC.AX 20/06/16
IMC Travelan and Protectyn Are Now Available For Sale in China-IMC.AX PRICE SENSITIVE16/06/16
IMC Immuron Extends Closing Date of $6M Rights Issue-IMC.AX 14/06/16
IMC Travelan to Reach Upto 1.5M New US Customers via Magellans-IMC.AX PRICE SENSITIVE14/06/16
IMC Immuron Company Presentation - May 2016-IMC.AX 31/05/16
IMC Immuron Rights Issue Offer Booklet (May 2016)-IMC.AX PRICE SENSITIVE31/05/16
IMC Letter to Ineligible Shareholders Regarding Rights Issue-IMC.AX 31/05/16
IMC Letter to Eligible Shareholders Regarding Rights Issue-IMC.AX 31/05/16
IMC Letter to Optionholders Regarding Rights Issue (May 2016)-IMC.AX 31/05/16
IMC Section 708AA Notice (Rights Issue)-IMC.AX 31/05/16
IMC Appendix 3B & 708A Notice-IMC.AX 31/05/16
IMC Immuron Announces $6M Rights Issue Offer-IMC.AX PRICE SENSITIVE31/05/16
IMC Trading halt-IMC.AX PRICE SENSITIVE27/05/16
IMC NASH Phase II Trial Reaches 50% Recruitment Milestone-IMC.AX PRICE SENSITIVE25/05/16
IMC Appendix 3B & 708A Notice-IMC.AX 16/05/16
IMC Immuron Announces E-Commerce Agreement with QBID in China-IMC.AX PRICE SENSITIVE09/05/16
IMC US Distribution Reach Expanded through McKesson-IMC.AX PRICE SENSITIVE28/04/16
IMC US Travelan Sales Network Widened by Allocation Inc Ptnrship-IMC.AX PRICE SENSITIVE19/04/16
IMC Appendix 3B & 708A Notice-IMC.AX 18/04/16
IMC Expansion of US Travelan Sales Following CVS Pharmacy Launch-IMC.AX PRICE SENSITIVE14/04/16
IMC Appendix 3B - Issuance of Securities-IMC.AX 13/04/16
IMC Appendix 4D - Half Yearly Report and AccountsPRICE SENSITIVE25/02/16
IMC Appendix 3B - Issue of Securities24/02/16
IMC Immuron Initiates Pre-Clinical Colitis Development ProgramPRICE SENSITIVE22/02/16
IMC Immuron Secures upto $1.7M Equity & Convertible Note FundingPRICE SENSITIVE17/02/16
IMC Immuron Receives $1.47M R&D Tax Concession RefundPRICE SENSITIVE04/02/16
IMC US Analyst Reports on Immuron Products and R&D Pipeline03/02/16
IMC Analyst Reports on Immuron IMM-529 C. difficile ProgramPRICE SENSITIVE14/01/16
IMC IMC Achieves Outstanding Results in C-Diff Recurrence StudyPRICE SENSITIVE12/01/16
IMC IMC Reports Highly Successful C-Diff Pre-Clinical ResultsPRICE SENSITIVE22/12/15
IMC Appendix 3B04/12/15
IMC Change of Director's Interest Notices x4 - (RA, PA, DP, SA)04/12/15
IMC Results of 2015 Immuron Annual General Meeting25/11/15
IMC Immuron 2015 Annual General Meeting Presentation25/11/15
IMC NASH Clinical Trial Surpasses 25% Patient Recruitment LevelPRICE SENSITIVE18/11/15
IMC IMC Signs US Travelan Sales Agreement with Medico-Mart IncPRICE SENSITIVE12/11/15
IMC Replay of Immuron CEO's Presentation at Microcap Conference10/11/15
IMC Appendix 3B - Exercise of Options09/11/15
IMC NASH Diagnostic Collaboration Agreement - OWL MetabolomicsPRICE SENSITIVE09/11/15
IMC IMC Signs US Travelan Sales P/ship with TravelCare WorldWide05/11/15
IMC Notice of Annual General Meeting & Explanatory Memorandum28/10/15
IMC Passport Health - Sales Partnership AgreementPRICE SENSITIVE26/10/15
IMC Change of Director's Interest Notice - (PA)23/10/15
IMC IMC to Present at RedChip Global Online Microcap Conference22/10/15
IMC 604 Change of Substantial Shareholder Interest (Grandlodge)21/10/15
IMC Appendix 3B - Exercise of Options19/10/15
IMC Appendix 3B - Exercise of Options30/09/15
IMC Appendix 3B - Exercise of Options18/09/15
IMC NASDAQ Listing on Hold Pending NASH Interim Analysis Results
01/06/17PRICE SENSITIVE
IMC Trading Halt
30/05/17PRICE SENSITIVE
IMC IMC Expands Agreement with US Army-3 Additional Therapeutics
16/05/17PRICE SENSITIVE
IMC Completion of Manufacturing of Drug Product for C-Diff Trial
10/05/17PRICE SENSITIVE
IMC Immuron - New Investor Corporate Presentation (May 2017)
09/05/17
IMC IMC Form F1 - US Registration Statement (Prelim. Prospectus)
09/05/17PRICE SENSITIVE
IMC Immuron Files Amended Form F-1 and New Investor Presentation
09/05/17
IMC Form 604 - Change in Substantial Shareholding (Authentics)
05/05/17
IMC Form 603 - Initial Substantial Shareholder (Authentics)
05/05/17
IMC Positive Results of IMM-124E in Acute Colitis Studies
18/04/17PRICE SENSITIVE
IMC Immuron Update on US Listing - Proceeding as Planned
11/04/17
IMC Immuron Update on Listing - Process Proceeding as Planned
11/04/17
IMC Immuron Files Amended Form F-1 with the SEC
10/04/17
IMC Director Appointment - Prof. Ravi Savarirayan
07/04/17
IMC Close of Recruitment of Phase II NASH Trial
06/04/17PRICE SENSITIVE
IMC Appendix 4D - Half Year Report and Accounts - Dec 2016
28/02/17PRICE SENSITIVE
IMC Immuron Completes Phase II NASH Clinical Trial Recruitment
20/02/17PRICE SENSITIVE
IMC Immuron Files Amended Form F-1 with the SEC
09/02/17
IMC First Patient in Pediatric Fatty-Liver Phase II Trial
06/02/17PRICE SENSITIVE
IMC NASH MOA Study commences with SanyalBio & Duke University
19/01/17PRICE SENSITIVE
IMC European/US Analyst - Immuron Moving to Forefront in NASH
18/01/17
IMC Gilead Pays $100M NASH Related Milestone to Phenex
09/01/17
IMC JNJ, BMS and Novartis Complete NASH Asset Transactions
06/01/17
IMC Immuron Files Form F-1 with the SEC
22/12/16
IMC Appendix 3B - Issue of Options Under ESOP
09/12/16
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)
07/12/16
IMC Appendix 3Y - Change of Director's Interest Notices (x4)
02/12/16
IMC Appendix 3B - Issue of Rights Issue Options & ESOP Shares
02/12/16
IMC Results of 2016 Annual General Meeting
29/11/16
IMC 2016 AGM Presentation
29/11/16
IMC Immuron Receives $1.6M R&D Tax Concession Refund
29/11/16PRICE SENSITIVE
IMC Notice of 2016 Annual General Meeting-IMC.AX
28/10/16
IMC Immurons NASH Phase II Trial Achieves 100 Patient Milestone-IMC.AX
28/10/16PRICE SENSITIVE
IMC Appendix 3Y - Change in Director's Interest Notice (DP)-IMC.AX
27/10/16
IMC Becoming a substantial holder-IMC.AX
17/10/16
IMC NASH Phase II Trial reaches 75% of Patient Recruitment-IMC.AX
10/10/16PRICE SENSITIVE
IMC NASH Assets In Demand - Allergan Acquires Tobira for US$1.7B-IMC.AX
05/10/16
IMC IMC - ASX - Appendix 3B (Rights Issue)-IMC.AX
04/10/16
IMC Immurons $6M Rights Issue Closes Oversubscribed-IMC.AX
04/10/16PRICE SENSITIVE
IMC Appendix 4E and Annual Report-IMC.AX
30/08/16PRICE SENSITIVE
IMC Appendix 4G-IMC.AX
30/08/16
IMC Immuron Expands Collaborate with US Navy-IMC.AX
30/08/16PRICE SENSITIVE
IMC US NIH to Fund Second IMC Fatty Liver Study - Pediatric NASH-IMC.AX
18/08/16PRICE SENSITIVE
IMC Travelan to be Stocked by US Distributor Medique Products-IMC.AX
08/08/16PRICE SENSITIVE
IMC Immuron to Seek Approval of Rights Issue Options at AGM-IMC.AX
02/08/16
IMC Immuron to Cooperate with Universities on Autism Research-IMC.AX
20/07/16PRICE SENSITIVE
IMC Immuron to repay outstanding Convertible Note in cash-IMC.AX
18/07/16PRICE SENSITIVE
IMC Form 604 -Change in Substantial Shareholding (Inverarey P/L)-IMC.AX
15/07/16
IMC Appendix 3Y - Change in Director's Interest Notices (x4)-IMC.AX
11/07/16
IMC Appendix 3B for Rights Issue & New Top 20 Shareholder List-IMC.AX
07/07/16
IMC Immuron Rights Issue Raises $5.33M-IMC.AX
05/07/16
IMC IMC Signs Shigella Vaccine Developmt Agreement with US Army-IMC.AX
21/06/16PRICE SENSITIVE
IMC Immuron Newsletter - June 2016-IMC.AX
20/06/16
IMC Travelan and Protectyn Are Now Available For Sale in China-IMC.AX
16/06/16PRICE SENSITIVE
IMC Immuron Extends Closing Date of $6M Rights Issue-IMC.AX
14/06/16
IMC Travelan to Reach Upto 1.5M New US Customers via Magellans-IMC.AX
14/06/16PRICE SENSITIVE
IMC Immuron Company Presentation - May 2016-IMC.AX
31/05/16
IMC Immuron Rights Issue Offer Booklet (May 2016)-IMC.AX
31/05/16PRICE SENSITIVE
IMC Letter to Ineligible Shareholders Regarding Rights Issue-IMC.AX
31/05/16
IMC Letter to Eligible Shareholders Regarding Rights Issue-IMC.AX
31/05/16
IMC Letter to Optionholders Regarding Rights Issue (May 2016)-IMC.AX
31/05/16
IMC Section 708AA Notice (Rights Issue)-IMC.AX
31/05/16
IMC Appendix 3B & 708A Notice-IMC.AX
31/05/16
IMC Immuron Announces $6M Rights Issue Offer-IMC.AX
31/05/16PRICE SENSITIVE
IMC Trading halt-IMC.AX
27/05/16PRICE SENSITIVE
IMC NASH Phase II Trial Reaches 50% Recruitment Milestone-IMC.AX
25/05/16PRICE SENSITIVE
IMC Appendix 3B & 708A Notice-IMC.AX
16/05/16
IMC Immuron Announces E-Commerce Agreement with QBID in China-IMC.AX
09/05/16PRICE SENSITIVE
IMC US Distribution Reach Expanded through McKesson-IMC.AX
28/04/16PRICE SENSITIVE
IMC US Travelan Sales Network Widened by Allocation Inc Ptnrship-IMC.AX
19/04/16PRICE SENSITIVE
IMC Appendix 3B & 708A Notice-IMC.AX
18/04/16
IMC Expansion of US Travelan Sales Following CVS Pharmacy Launch-IMC.AX
14/04/16PRICE SENSITIVE
IMC Appendix 3B - Issuance of Securities-IMC.AX
13/04/16
IMC Appendix 4D - Half Yearly Report and Accounts
25/02/16PRICE SENSITIVE
IMC Appendix 3B - Issue of Securities
24/02/16
IMC Immuron Initiates Pre-Clinical Colitis Development Program
22/02/16PRICE SENSITIVE
IMC Immuron Secures upto $1.7M Equity & Convertible Note Funding
17/02/16PRICE SENSITIVE
IMC Immuron Receives $1.47M R&D Tax Concession Refund
04/02/16PRICE SENSITIVE
IMC US Analyst Reports on Immuron Products and R&D Pipeline
03/02/16
IMC Analyst Reports on Immuron IMM-529 C. difficile Program
14/01/16PRICE SENSITIVE
IMC IMC Achieves Outstanding Results in C-Diff Recurrence Study
12/01/16PRICE SENSITIVE
IMC IMC Reports Highly Successful C-Diff Pre-Clinical Results
22/12/15PRICE SENSITIVE
IMC Appendix 3B
04/12/15
IMC Change of Director's Interest Notices x4 - (RA, PA, DP, SA)
04/12/15
IMC Results of 2015 Immuron Annual General Meeting
25/11/15
IMC Immuron 2015 Annual General Meeting Presentation
25/11/15
IMC NASH Clinical Trial Surpasses 25% Patient Recruitment Level
18/11/15PRICE SENSITIVE
IMC IMC Signs US Travelan Sales Agreement with Medico-Mart Inc
12/11/15PRICE SENSITIVE
IMC Replay of Immuron CEO's Presentation at Microcap Conference
10/11/15
IMC Appendix 3B - Exercise of Options
09/11/15
IMC NASH Diagnostic Collaboration Agreement - OWL Metabolomics
09/11/15PRICE SENSITIVE
IMC IMC Signs US Travelan Sales P/ship with TravelCare WorldWide
05/11/15
IMC Notice of Annual General Meeting & Explanatory Memorandum
28/10/15
IMC Passport Health - Sales Partnership Agreement
26/10/15PRICE SENSITIVE
IMC Change of Director's Interest Notice - (PA)
23/10/15
IMC IMC to Present at RedChip Global Online Microcap Conference
22/10/15
IMC 604 Change of Substantial Shareholder Interest (Grandlodge)
21/10/15
IMC Appendix 3B - Exercise of Options
19/10/15
IMC Appendix 3B - Exercise of Options
30/09/15
IMC Appendix 3B - Exercise of Options
18/09/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
7.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $21.88M
Open High Low Value Volume
7.6¢ 7.6¢ 7.5¢ $9.071K 120.6K

Buyers (Bids)

No. Vol. Price($)
1 57518 7.5¢
 

Sellers (Offers)

Price($) Vol. No.
7.9¢ 10000 1
View Market Depth
Last trade - 15.45pm 22/11/2024 (20 minute delay) ?
IMC (ASX) Chart

Top Stories

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due to organised crime links.
Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in the hands of two industry giants. But what does this mean for Australians @ greater access to cheaper medicines or the loss of small, commun...
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Sales growth pushes Lovisa's fortunes (and shares) upwards Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.